222 related articles for article (PubMed ID: 23686785)
1. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
Eslin D; Lee C; Sankpal UT; Maliakal P; Sutphin RM; Abraham L; Basha R
Tumour Biol; 2013 Oct; 34(5):2781-9. PubMed ID: 23686785
[TBL] [Abstract][Full Text] [Related]
2. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.
Eslin D; Sankpal UT; Lee C; Sutphin RM; Maliakal P; Currier E; Sholler G; Khan M; Basha R
Mol Carcinog; 2013 May; 52(5):377-86. PubMed ID: 22213339
[TBL] [Abstract][Full Text] [Related]
3. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
4. Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.
Patil S; Sankpal UT; Hurtado M; Bowman WP; Murray J; Borgmann K; Ghorpade A; Sutphin R; Eslin D; Basha R
Gene; 2019 Jul; 705():67-76. PubMed ID: 30991098
[TBL] [Abstract][Full Text] [Related]
5. Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.
Shelake S; Sankpal UT; Paul Bowman W; Wise M; Ray A; Basha R
Invest New Drugs; 2017 Apr; 35(2):158-165. PubMed ID: 28025760
[TBL] [Abstract][Full Text] [Related]
6. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
Hurtado M; Sankpal UT; Kaba A; Mahammad S; Chhabra J; Brown DT; Gurung RK; Holder AA; Vishwanatha JK; Basha R
Cell Physiol Biochem; 2018; 51(4):1894-1907. PubMed ID: 30504717
[TBL] [Abstract][Full Text] [Related]
7. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
8. Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation.
Shelake S; Eslin D; Sutphin RM; Sankpal UT; Wadwani A; Kenyon LE; Tabor-Simecka L; Bowman WP; Vishwanatha JK; Basha R
Int J Dev Neurosci; 2015 Nov; 46():92-9. PubMed ID: 26287661
[TBL] [Abstract][Full Text] [Related]
9. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
Oncotarget; 2016 Jan; 7(3):3186-200. PubMed ID: 26672603
[TBL] [Abstract][Full Text] [Related]
10. Anti-leukemic response of a NSAID, tolfenamic acid.
Sutphin RM; Connelly SF; Lee CM; Sankpal UT; Eslin D; Khan M; Pius H; Basha R
Target Oncol; 2014 Jun; 9(2):135-44. PubMed ID: 23609055
[TBL] [Abstract][Full Text] [Related]
11. Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells.
Shelake S; Sankpal UT; Eslin D; Bowman WP; Simecka JW; Raut S; Ray A; Basha R
Apoptosis; 2019 Feb; 24(1-2):21-32. PubMed ID: 30610505
[TBL] [Abstract][Full Text] [Related]
12. Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation.
Sankpal UT; Lee CM; Connelly SF; Kayaleh O; Eslin D; Sutphin R; Goodison S; Adwan L; Zawia NH; Lichtenberger LM; Basha R
Cell Physiol Biochem; 2013; 32(3):675-86. PubMed ID: 24030139
[TBL] [Abstract][Full Text] [Related]
13. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors.
Pathi S; Li X; Safe S
Mol Carcinog; 2014 Feb; 53 Suppl 1():E53-61. PubMed ID: 23670891
[TBL] [Abstract][Full Text] [Related]
14. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.
Liu X; Abdelrahim M; Abudayyeh A; Lei P; Safe S
Mol Cancer Ther; 2009 May; 8(5):1207-17. PubMed ID: 19435870
[TBL] [Abstract][Full Text] [Related]
15. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
[TBL] [Abstract][Full Text] [Related]
16. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.
Colon J; Basha MR; Madero-Visbal R; Konduri S; Baker CH; Herrera LJ; Safe S; Sheikh-Hamad D; Abudayyeh A; Alvarado B; Abdelrahim M
Invest New Drugs; 2011 Feb; 29(1):41-51. PubMed ID: 19851711
[TBL] [Abstract][Full Text] [Related]
17. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.
Papineni S; Chintharlapalli S; Abdelrahim M; Lee SO; Burghardt R; Abudayyeh A; Baker C; Herrera L; Safe S
Carcinogenesis; 2009 Jul; 30(7):1193-201. PubMed ID: 19406933
[TBL] [Abstract][Full Text] [Related]
18. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.
Basha R; Connelly SF; Sankpal UT; Nagaraju GP; Patel H; Vishwanatha JK; Shelake S; Tabor-Simecka L; Shoji M; Simecka JW; El-Rayes B
J Nutr Biochem; 2016 May; 31():77-87. PubMed ID: 27133426
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
Choi ES; Shim JH; Jung JY; Kim HJ; Choi KH; Shin JA; Nam JS; Cho NP; Cho SD
Cancer Sci; 2011 Apr; 102(4):742-8. PubMed ID: 21241418
[TBL] [Abstract][Full Text] [Related]
20. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
